The Clinical Research Of Danggui Buxue Decoctionand R-HuEPO In Prevention Of Prematurity Anemia

PurposeIn this study, methodology of strengthening the spleen and replenishing Qi was utilized, in order to discuss the clinical efficacy of Danggui Buxue Decoction and EPO in the prevention of prematurity anemia, with Danggui Buxue Decoction being taken orally, and its influences on immunologic function of prematurity, and to evaluate the medication safety of Danggui Buxue Decoction.MethodologyThe sampling size was 80, who were hospitalized between October 1,2014 and October 31,2015 in the Neonatal intensive care unit in the affiliated Nanhai maternity and children’s Hospital of Guangzhou University of Chinese Medicine, and whose age was between 28 to 32 weeks. The sample was divided into two groups--treatment group and controlled group — 40 each (After eliminating loss cases, and finally into the statistics, a total of 77 cases, control group in which 38 cases,39 cases in treatment group). For controlled group, undertake hypodermic injection of EPO 250 IU/kg each time, one time every two days,3 times per week,4 weeks a course. In addition to the same treatment in controlled group, for treatment group take orally Danggui Buxue Decoction (composition:Huangqi granule lg, Danggui granule 0.3g), at the time of half an hour after feeding,20ml warm water reconstitution, and taking in the morning and at night, two weeks a course. Nasal feeding can replace oral feeding in case. In the second week of birth, take orally Iron Proteinsuccinylate Oral Solution lml per time (amount to elemental iron 2.6mg per time) for both groups,2 times a day, and vitamin E 25mg/d, treating with blood transfusion in case, other treatments in accordance with conventional therapy. Observe the anemia cases of prematurity in both groups before and after treatment in the 2nd,4th,6th week; Before and after the treatment, in 2nd,4th,6th week, sample venous blood (or peripheral blood) to examine blood routine, content of SF, meanwhile observe changes of IgA、IgG、IgM、、CD4+、 CD8+、CD4+/CD8+ for the immunologic functions of the two groups, for example, the cases which need blood transfusion, number of infected cases in the hospital, increase or decrease in body mass, and number of cases of feeding intolerance. Compare the dynamics of all the indexes of prematurity in the two groups, and evaluate the medication safety of Danggui Buxue Decoction.Results1. In the 2nd,4th, and 6th week of treatment, the number of anemia cases in controlled group was 26, and 28 respectively, while that in the treatment group was 11,17, and 19 respectively. Undertake statistical analysis at each time between the two groups, and the difference was statistically significant (P<0.05).2. In controlled group, the percentage who needed blood transfusion was 26.3%, whereas that in treatment group was 10.3%. The difference was statistically significant (P<0.05).3. The content of RBC、Hb、Hct and SF in both groups in the 2nd,4th, and 6th week of treatment both continued to decrease. However, at each time the content of RBC、Hb、 Hct and SF in treatment group was higher than in the controlled group, and the difference was statistically significant (P<0.05).4. The rising magnitude of IgA、IgG and IgM of prematurity in treatment group was higher than that in the controlled group at each time. The difference was statistically significant (P<0.05). Meanwhile, when focusing on intra-group comparison, before and after the treatment, the differences in IgA、IgG and IgM were statistically significant (P<0.05).5. After treatment, prematurity’s CD4+ value in treatment group had a higher rising magnitude than that in the controlled group, and CD8+ value in treatment group had a lower falling magnitude. Inter group difference was statistically significant (P<0.05). Although CD4+/CD8+ values rose after the treatment, the difference was statistically insignificant (P>0.05). Meanwhile, when it comes to intra-group comparison, before and after the treatment, the differences in CD4+、CD8+、CD4+/CD8+ values were statistically significant (P<0.05).6. The infected rate in treatment group in hospital was 2.6% whereas that in controlled group was 7.9%. Obviously, the infected rate in treatment group was lower than that in the controlled group, and the difference was statistically insignificant (P>0.05).7. After treatment, the increasing magnitude of body mass in the treatment group was higher than that in the controlled group. And the difference was statistically significant (P<0.05). 8. Feeding intolerance occurrence rate in treatment group was 10.3%, while that in the controlled group was 21.1%. And the difference was statistically insignificant (P>0.05).9. No severe untoward effect happened after taking Danggui Buxue Decoction.Gonclusion1. Danggui Buxue Decoction, combined with EPO, can decrease the number of occurrence cases of prematurity anemia at each time, decrease the occurrence rate of anemia, and is effective in the prevention of prematurity anemia.2. Danggui Buxue Decoction, combined with EPO, can decrease the number of prematurity blood transfusion, decrease blood transfusion rate.3. Danggui Buxue Decoction and EPO can both by adjusting T lymphocyte subgroup and immunenoglobulin to improve immune function to strengthen prematurity’s immunity.4. Danggui Buxue Decoction can promote the increase of prematurity’ s body mass.5. Danggui Buxue Decoction is safe and reliable in prevention of prematurity anemia, do not increase the risk of prematurity’s feeding intolerance.